April 22 (Reuters) - The U.S. FDA approved ImmunityBio's combination therapy to treat a type of bladder cancer, the regulator said on Monday, which would help bring the company's first product to market. (Reporting by Puyaan Singh and Pratik Jain in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.23 USD | +6.86% | +11.25% | +24.10% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.10% | 4.31B | |
+14.84% | 121B | |
+18.31% | 112B | |
+2.94% | 22.72B | |
-18.26% | 20.82B | |
-18.47% | 16.66B | |
-42.36% | 16.36B | |
-14.23% | 16.19B | |
-0.68% | 13.17B | |
+21.87% | 11.11B |
- Stock Market
- Equities
- IBRX Stock
- News ImmunityBio, Inc.
- U.S. FDA approves ImmunityBio's bladder cancer therapy